Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review
Endocrinology, Diabetes & Metabolism · 2026
DOI: 10.1002/edm2.70250 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2026. Verfasst von Eric J Gutierrez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health and Kinesiology, Purdue University, West Lafayette, Indiana, USA. Hauptthemen laut MEDLINE: Glycation End Products, Advanced, Tendon Injuries, Diabetes Mellitus, Diabetes Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIH HHS, National Institutes of Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Tendon injuries in individuals with diabetes are difficult to reverse, and the mechanisms driving poor healing, extracellular matrix disruption, and altered biomechanics remain poorly understood. Many individuals with prediabetes or diabetes are also overweight or obese, and increased visceral adiposity alters adipokine levels and promotes chronic inflammation. While multiple factors influence tendon healing and extracellular matrix (ECM) remodelling, we suggest that circulating advanced glycation end‐products (AGEs) may drive delayed healing, collagen disorganization, and compromised biomechanical properties in diabetes.
Methods
A comprehensive narrative review of the literature was conducted using PubMed and Embase to synthesize current and emerging evidence on the relationship between AGEs, tendon properties, and tendon healing in diabetes. Experimental, translational, and clinical studies, as well as relevant review articles involving cell, animal, and human models, were critically analysed.
Results
This narrative review explores the limited evidence linking serum AGE accumulation and Receptor for Advanced Glycation End‐Product (RAGE) activation to tendon pathology and poor healing. Traditionally, tendon dysfunction in diabetes has been attributed to non‐enzymatic collagen crosslinking. However, there is mixed evidence demonstrating increased tendon AGE content or stiffness in diabetic patients compared to age‐matched controls, suggesting alternative mechanisms. Therefore, we outline recent in vitro, animal, and human studies on AGE and RAGE in tendons and propose future directions.
Conclusion
We propose that a systemic rise in serum AGEs impairs tendon healing by activating RAGE and disrupting cellular pathways required for repair. Future studies investigating the role of AGEs and other circulating factors may provide insights into the high incidence of tendon injuries and impaired healing in individuals with diabetes and related metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health and Kinesiology, Purdue University, West Lafayette, Indiana, USA.
- Purdue Military Research Institute, West Lafayette, Indiana, USA.
- School of Kinesiology, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Eric J Gutierrez, Chad C Carroll
Förderung
- NIAMS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Gutierrez, E. J., Mitevski, L. E., Haus, J. M., & Carroll, C. C. (2026). Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70250
Vancouver
Gutierrez EJ, Mitevski LE, Haus JM, Carroll CC. Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review. Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70250
BibTeX
@article{Gutierrez2026,
author = {Gutierrez, Eric J and Mitevski, Lauren E and Haus, Jacob M and Carroll, Chad C},
title = {Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
doi = {10.1002/edm2.70250}
}
EUVIMED